4.3 Article

The NETest The Clinical Utility of Multigene Blood Analysis - in the Diagnosis and Management of Neuroendocrine Tumors

Journal

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ecl.2018.05.002

Keywords

NETest; Multigene blood analysis; Neuroendocrine tumors; Peptide receptor radionuclide therapy; Bronchopulomary carcinoid; Transcript; Progression; PCR; Blood; Biomarker

Funding

  1. NCI NIH HHS [P30 CA008748] Funding Source: Medline

Ask authors/readers for more resources

The neuroendocrine neoplasms test (NETest) is a multianalyte liquid biopsy that measures neuroendocrine tumor gene expression in blood. This unique signature precisely defines the biological activity of an individual tumor in real time. The assay meets the 3 critical requirements of an optimal biomarker: diagnostic accuracy, prognostic value, and predictive therapeutic assessment. NETest performance metrics are sensitivity and specificity and in head-to-head comparison are 4-fold to 10-fold more accurate than chromogranin A. NETest accurately identifies completeness of surgery and response to somatostatin analogs. Clinical registry data demonstrate significant clinical utility in watch/wait programs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available